Clinical Evaluation on the Treatment of Early Diabetic Nephropathy by Valsartan Combined with Kallidinogenase

Objective To investigate the effect of angiotensinⅡreceptor antagonist valsartan combined with kallidinogenase on early diabetic nephropathy.Methods Forty of early type II diabetic nephropathy patients,hospitalized in our department between June 2008 and December 2009,were randomly divided into control and treatment group(n=20 for each group).The patients in the control group were treated with regular therapy(antidiabetic drug and valsartan);the patients in the treatment group were treated with the regular therapy combined with kallidinogenase.Results Urine albumin excretion(UAE)at 24 h following treatment was markedly decreased in the treatment group compared to the control group(P0.05).However,the changes in creatinine and urea nitrogen had no significant difference between the two groups(P0.05).Conclusions AngiotensinⅡreceptor antagonist valsartan combined with kallidinogenase can reduce obviously urine protein in type II diabetic nephropathy patients and delay the development of its pathological process.The combination therapy is thus safe and effective and can be employed in clinical practice.